/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Can Fite Biopharma Ltd share price today is $3.72, up -8.15%. The stock opened at $3.97 against the previous close of $4.05, with an intraday high of $4 and low of $3.71.

style

pb-0

Can Fite Biopharma Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$3.72 -0.0815(-8.15%) CANF at 13 Mar 2026 12:21 PM Biotechnology

Lowest Today 3.71

Highest Today 4

Today’s Open 3.97

Prev. Close 4.05

52 Week High 46.60

52 Week Low 3.36

Day’s Range: Low 3.71 High 4

52-Week Range: Low 3.36 High 46.60

Can Fite Biopharma Ltd Institutional Holdings

Can Fite Biopharma Ltd Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Can Fite Biopharma Ltd Fundamentals

Market Cap 15.24 M

PB Ratio 1.2673

PE Ratio 0.0

Enterprise Value -0.96 M

Total Assets 9.12 M

Volume 91178

Can Fite Biopharma Ltd Company Financials

Annual Revenue FY23:785000 0.8M, FY22:810000 0.8M, FY21:853000 0.9M, FY20:763000 0.8M, FY19:2032000 2.0M

Annual Profit FY23:null 0.0M, FY22:810000 0.8M, FY21:853000 0.9M, FY20:763000 0.8M, FY19:2032000 2.0M

Annual Net worth FY23:-9001000 -9.0M, FY22:-10236000 -10.2M, FY21:-12595000 -12.6M, FY20:-14806000 -14.8M, FY19:-13052000 -13.1M

Quarterly Revenue Q2/2025:101000 0.1M, Q1/2025:101000 0.1M, Q2/2024:158000 0.2M, Q4/2023:155000 0.2M, Q3/2023:196000 0.2M

Quarterly Profit Q2/2025:101000 0.1M, Q1/2025:101000 0.1M, Q2/2024:158000 0.2M, Q4/2023:155000 0.2M, Q3/2023:196000 0.2M

Quarterly Net worth Q2/2025:-2438000 -2.4M, Q1/2025:-2438000 -2.4M, Q2/2024:-1978500 -2.0M, Q4/2023:-1652000 -1.7M, Q3/2023:-1762000 -1.8M

About Can Fite Biopharma Ltd & investment objective

Company Information Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Organisation Biotechnology

Employees 5

Industry Biotechnology

CEO Mr. Motti Farbstein

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*